Christopher Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Christopher Thomas has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
A. C. Wootten
Smiling Mind, Melbourne, Victoria, Australia
1 shared publicationD. P. McKenzie
Epworth Research Institute, Epworth HealthCare, Richmond, Victoria, Australia
1 shared publication- Dean P. McKenzie
Office for Research, Epworth HealthCare, Melbourne, Victoria, Australia
1 shared publication - Edward A. Levine
Section of Surgical Oncology, Department of General Surgery, Wake Forest University, Winston-Salem, NC, USA.
1 shared publication - Elena M. Fenu
Department of Pathology and Laboratory Medicine Hospital of the University of Pennsylvania Philadelphia Pennsylvania USA
1 shared publication - Michael B. Rothberg
Department of Urology Wake Forest Baptist Medical Center Winston-Salem NC USA
1 shared publication
Latest Publications
- Open Access
- 1 November 2020
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2020, 1-6
Pathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma
Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete response to neoadjuvant nivolumab plus ipilimumab in a patient with a 13.9cm left renal mass and significant retroperitoneal and iliac lymphadenopathy, classified as intermediate-risk mRCC. We discuss and review the literature on complete responses after systemic therapy and the ability to predict who has undergone a complete response in the face of residual radiographic evidence of disease.
- 1 November 2020
- Published by Hindawi Limited in Case Reports in Urology
- Vol. 2020, 1-6
Open AccessPathologic Complete Response to Neoadjuvant Nivolumab/Ipilimumab in a Patient with Metastatic Renal Cell Carcinoma
Nivolumab plus ipilimumab represents an effective combination of checkpoint inhibitors that can lead to a durable response with minimal toxicity in patients with metastatic renal cell carcinoma (mRCC). We present a case of a pathologic complete response to neoadjuvant nivolumab plus ipilimumab in a patient with a 13.9cm left renal mass and significant retroperitoneal and iliac lymphadenopathy, classified as intermediate-risk mRCC. We discuss and review the literature on complete responses after systemic therapy and the ability to predict who has undergone a complete response in the face of residual radiographic evidence of disease.
- 20 April 2020
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 50 (8) , e13249
Relative risks and odds ratios: Simple rules on when and how to use them
Aim: Relative risks and odds ratios are widely reported in the medical literature, but can be very difficult to understand. We sought to further clarify these important indices.Methods: We illustrated both relative risks and odds ratios using bar charts, then looked at the types of study for which each statistic is suited. We demonstrated calculation of relative risks and odds ratios through analysis of tabled data from a recent published longitudinal study, using a 2 × 2 table and R, the open‐source statistical programming language. Simple rules for when and how to use relative risks and odds ratios are presented.Conclusion: Understanding the difference between relative risks and odds ratios and when and how to use them may aid clinical interpretation, dissemination and translation of research findings.
- 20 April 2020
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 50 (8) , e13249
Relative risks and odds ratios: Simple rules on when and how to use them
Aim: Relative risks and odds ratios are widely reported in the medical literature, but can be very difficult to understand. We sought to further clarify these important indices.Methods: We illustrated both relative risks and odds ratios using bar charts, then looked at the types of study for which each statistic is suited. We demonstrated calculation of relative risks and odds ratios through analysis of tabled data from a recent published longitudinal study, using a 2 × 2 table and R, the open‐source statistical programming language. Simple rules for when and how to use relative risks and odds ratios are presented.Conclusion: Understanding the difference between relative risks and odds ratios and when and how to use them may aid clinical interpretation, dissemination and translation of research findings.
- 20 February 2018
- Published by Wiley in European Journal of Cancer Care
- Vol. 27 (2) , e12827
The impact of sexual orientation on body image, self-esteem, urinary and sexual functions in the experience of prostate cancer
Prostate cancer (PCa) poses a large health burden globally. Research indicates that men experience a range of psychological challenges associated with PCa including changes to identity, self‐esteem and body image. The ways in which sexual orientation plays a role in the experience of PCa, and the subsequent impact on quality of life (QoL), body image and self‐esteem have only recently been addressed. By addressing treatment modality, where participant numbers were sufficient, we also sought to explore whether gay (homosexual) men diagnosed with PCa (PCaDx) and with a primary treatment modality of surgery would report differences in body image and self‐esteem compared with straight (heterosexual) men with PCaDx with a primary treatment modality of surgery, compared with gay and straight men without PCaDx. The results of our study identified overall differences with respect to PCaDx (related to urinary function, sexual function and health evaluation), and sexual orientation (related to self‐esteem), rather than interactions between sexual orientation and PCaDx. Gay men with PCaDx exhibited higher levels of urinary functioning than straight men with PCaDx, the difference being reversed for gay and straight men without PCaDx; but this result narrowly failed to achieve statistical significance, suggesting a need for further research, with larger samples.
- 20 February 2018
- Published by Wiley in European Journal of Cancer Care
- Vol. 27 (2) , e12827
The impact of sexual orientation on body image, self-esteem, urinary and sexual functions in the experience of prostate cancer
Prostate cancer (PCa) poses a large health burden globally. Research indicates that men experience a range of psychological challenges associated with PCa including changes to identity, self‐esteem and body image. The ways in which sexual orientation plays a role in the experience of PCa, and the subsequent impact on quality of life (QoL), body image and self‐esteem have only recently been addressed. By addressing treatment modality, where participant numbers were sufficient, we also sought to explore whether gay (homosexual) men diagnosed with PCa (PCaDx) and with a primary treatment modality of surgery would report differences in body image and self‐esteem compared with straight (heterosexual) men with PCaDx with a primary treatment modality of surgery, compared with gay and straight men without PCaDx. The results of our study identified overall differences with respect to PCaDx (related to urinary function, sexual function and health evaluation), and sexual orientation (related to self‐esteem), rather than interactions between sexual orientation and PCaDx. Gay men with PCaDx exhibited higher levels of urinary functioning than straight men with PCaDx, the difference being reversed for gay and straight men without PCaDx; but this result narrowly failed to achieve statistical significance, suggesting a need for further research, with larger samples.